Terrace Biopharma Advisors

Our Services

Corporate Strategy

Identify strengths, risks, and challenges of unique business plans across multiple stratifications (macro, sector, indication, subpopulation, mechanism of action, asset, trial design, etc.)
Determine current and future value potential and optimize inflection points for value creation via analysis of pipeline breadth and depth, competitive landscape, future internal and external news flow, upcoming milestones, and macro headwinds and tailwinds
Competitive market analysis tracking frequency, timing, venue, and format of major company announcements and milestone execution for maximal impact
Identify, anticipate, compare, contrast, and monitor competitor asset development and clinical trial design
Create, modify, refine, and optimize corporate messaging including presentation decks, call scripts, press releases, and quarterly material

Investor Relations

Corporate Strategy

Leverage wide network of relationships with institutional public, private, and venture investors
Raise company profile to establish and reinforce management credibility and reputation
Generate and maintain investor support for realistic and sustainable valuation
Develop and expand relationships with sell-side research analysts
Monitor sell-side coverage and track investor sentiment
Establish targeting and outreach plans with established objectives and milestones
Plan, design, prepare, and execute client events, including conference 1x1 schedules, non-deal roadshows, Analyst and R&D Days, and KOL events
Anticipate and identify potential inbound questions and prepare public-facing management for investor and analyst interactions
Source and compile investor feedback to maintain dialogue and optimize future engagements

Our Team

Founder, President

Michael V. Morabito, Ph.D. is a seasoned advisor for biopharma executive teams, leveraging his experiences and market insight to partner with biotech management teams to provide corporate advisory, investor relations, corporate communications, and financial analysis services. He has represented therapeutics companies of all sizes, from large cap to nano cap, in his experience on Wall Street. Throughout his scientific and financial career, Michael’s expertise includes metabolic diseases (featuring NASH), immuno-oncology, diabetes, RNA editing, CNS and behavioral disease, cardiology, endocrinology, and multiple rare diseases.

Prior to founding Terrace Biopharma Advisors, Michael’s experience as a Managing Director at Solebury Strategic Communications (formerly Solebury Trout) featured leading advisory teams for >20 different biopharma clients to provide strategic insight and advice for investor relations and corporate communications. Michael additionally has Wall Street experience as a sell-side equity research analyst for SMid-Cap Biotechnology companies at both Credit Suisse and Chardan Capital Markets, where he covered the NASH space and other metabolic diseases as well as targeted and immuno-oncology companies. Michael was also exposed to the breadth of the entire therapeutics market while on the large-cap US Pharma team at Credit Suisse.

Prior to entering equity research, Michael spent 15 years as an academic researcher, studying the CNS control of feeding behavior and metabolism as a post-doctoral researcher at Columbia University. Michael received his Ph.D. in Neuroscience from Vanderbilt University, where he studied RNA editing and pharmacology of the serotonin 2c receptor (5-HT2CR) and its impacts on feeding behavior, metabolism, and development. His work is featured in 13 publications, earning multiple financial research awards.